Our website uses cookies to make navigation as functional as possible and to perform statistics on its usage. Should you wish to receive more information, or deny your consent to all or some of the cookies, please click here. By continuing to browse this website, you will be accepting our cookies.
14 May 2020

25th EHA Congress: Menarini Ricerche discloses first results from the clinical study on SEL24/MEN1703

Pomezia, Italy, May 14th, 2020 –Menarini Ricerche announces the completion of the dose escalation part  of the First in Human, phase I/II DIAMOND trial (CLI24-001; NCT03008187) currently ongoing to evaluate SEL24/MEN1703, a first in class, oral dual PIM/FLT3 inhibitor in development for the treatment of acute myeloid leukemia (AML). The results will be disclosed at the 25th EHA virtual meeting with the e-poster entitled “Results of the dose escalation part of DIAMOND trial (CLI24-001): first in human study of SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor, in patients with acute myeloid leukemia” (EP604).

The primary objectives of the dose escalation part of the study were the identification of dose limiting toxicities, the determination of the maximum tolerated dose and recommended dose for the phase 2 part of the study, as well as characterization of the pharmacokinetics of SEL24/MEN1703 in AML – relapsed or refractory as well previously untreated - patients unsuitable for chemotherapy. Throughout the dose escalation part, SEL24/MEN1703 showed an acceptable safety profile up to the recommended dose established at 125 mg/day (14 days ON – 7 days OFF in 21-days cycles). Initial evidence of single agent efficacy was observed with 1 CR and 1 CRi in elderly patients who had exhausted standard therapeutic options. Cohort Expansion study in relapsed/refractory AML patients will further investigate the single agent activity and the safety profile of SEL24/MEN1703.

“The promising results from the dose-escalation phase of the DIAMOND trial provide a strong rationale to progress to the cohort expansion phase of the study” said Dirk Laurent, Global Therapeutic Area Head - Oncology of Menarini Ricerche. “We look forward to further revealing the potential of the SEL24/MEN1703 program to the benefit of AML patients who need innovative and effective therapeutic options”.